The US drug agency on 17 September cleared Fayuvi for children with MPS IIIA and named Ultragenyx as the holder. Notes in the 2-to-5-year group were set against an untreated historical control. The label lists raised liver enzymes, nausea, fever and reduced blood counts among reactions. A thrombotic microangiopathy warning sits on the label. Steroids start one day before the infusion and run at least 8 weeks.
On 17 September the US drug agency cleared Fayuvi for children living with MPS IIIA, the Sanfilippo A form, and wrote Ultragenyx as the holder. Notes in the 2-to-5-year group were set against an untreated historical control. The retained card is that agency notice, not a new manuscript. Readers should treat the comparison as the agency's chosen benchmark for this label.[1]
The notice lists Fayuvi as a single infusion product from Ultragenyx. This slot does not add an outside clinic write-up. How the product is described belongs on the label. Nothing here is a new trial chapter. The retained pool card is the clearance note itself.[1]
The label lists raised liver enzymes, nausea, fever and reduced blood counts among reactions. A thrombotic microangiopathy warning sits on the label. Steroids start one day before the infusion and run at least 8 weeks. Those risk lines travel with the same 17 September notice. The retained 17 September notice is the only pool card for this clearance.[1]
